DUBLIN and NEW YORK, Jan. 7, 2016 / PRNewswire / – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the acquisition of Anterios, Inc., a clinical-stage biopharmaceutical company developing a novel delivery system generation and prescription botulinum toxin products. Under the agreement, Allergan acquired Anterios for an upfront payment of $ 90 million and potential development and commercialization milestone payments related to NDS ™, Anterios’ proprietary platform delivery technology that enables local and targeted delivery of neurotoxins through the skin without the need for injections.
In addition to NDS ™, Allergan has acquired the worldwide rights to ANT-1207, an experimental formulation of botulinum toxin type A in development for the potential treatment of hyperhidrosis (excessive sweating), acne and wrinkles. crow’s feet.
NDS ™ platform technology and ANT-1207 add to Allergan’s strong neurotoxin pipeline, with BOTOX® Cosmetic (onabotulinumtoxinA) currently in development for the treatment of forehead wrinkles, masseter hypertrophy and platysma and BOTOX® Therapeutic bands in development for osteoarthritis and depression.
“The acquisition of Anterios reinforces Allergan’s commitment to innovation and maintaining its leadership position in the development and commercialization of neurotoxins,” said David nicholson, Executive Vice President and President, Global Brand Research and Development at Allergan. “Our team at Allergan has pioneered the development and commercialization of BOTOX®, the market-leading neurotoxin used in both medical aesthetics and medicine. This acquisition demonstrates our ability to apply our tremendous scientific leadership in neurotoxins to further expand our already deep neurotoxin pipeline by delivering a novel delivery system and formulations that are attractive to both patients and physicians. “
“Allergan has a long history in dermatology and aesthetics, a deep business and development network across these professional communities, and a strong commitment to innovation. -1207 to the next stage of development and eventual commercialization, ”said Jon edelson, MD, CEO and Founder of Anterios.
“The potential of a new delivery system like NDS ™ and a novel topical neurotoxin is exciting for the medical dermatology and aesthetic communities, as our patients seek non-invasive approaches to treat their skin conditions. and aesthetic ”, declared William Coleman, III, MD, clinical professor of dermatology and assistant professor of plastic surgery, Tulane Health Science Center. “Providing products offering an improved delivery mechanism and an effective topical formulation to today’s injectable botulinum toxin products would be an important step forward for our specialty. ”
Prior to closing, Anterios transferred certain assets to a new company, Eirion Therapeutics, Inc., funded by Anterios shareholders. The new entity also retains certain non-exclusive rights to ANT-1207.
Allergan plc (NYSE: AGN), headquartered at Dublin, Ireland, is a unique global pharmaceutical company and a leader in a new business model – Growth Pharma. Allergan is focused on the development, manufacture and marketing of innovative brand name pharmaceuticals, high quality generic and over-the-counter drugs, and biologics for patients around the world.
Allergan markets a portfolio of premier products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women’s health, urology, cardiovascular and anti- infectious diseases, and operates the third largest generics, providing patients around the world with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the largest development pipelines in the pharmaceutical industry and a leading position in submitting generic product applications globally.
With business operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives. .
For more information, visit the Allergan website at www.allergan.com.
Statements in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan’s current outlook on trends and information existing as of the date of this release. Except as expressly required by law, Allergan disclaims any intention or obligation to update these forward-looking statements. Actual results could differ materially from Allergan’s current expectations depending on a number of factors affecting Allergan’s business. These factors include, among others, difficulty in predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and prices; market acceptance and continued demand for Allergan’s products; risks associated with acquisitions, mergers and joint ventures; manufacturing difficulties or delays; and other risks and uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including, but not limited to, Allergan’s quarterly report on Form 10-Q for the quarter ended. September 30, 2015. Except as expressly required by law, Allergan disclaims any intention or obligation to update these forward-looking statements.
SOURCE Allergan plc